Lv21
136 积分 2021-02-19 加入
Goals for DMPK During Drug Optimizations
3天前
已完结
Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase
5天前
已完结
Developing analytical ion exchange chromatography methods for antibody drug conjugates containing the hydrolysis-prone succinimide-thioether conjugation chemistry
19天前
已完结
Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
19天前
已完结
KRASG12C inhibitor: combing for combination
24天前
已完结
Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics
24天前
已完结
KRAS inhibitors in drug resistance and potential for combination therapy
24天前
已完结
Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates
24天前
已完结
Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
28天前
已完结
Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6 Targeting Antibody Drug Conjugate
28天前
已完结
皖公网安备34019202002308
